BioRestorative Therapies, Inc.
- Jurisdiction
United States - LEI
549300I1PJXVT7ISIV91 - ISIN
US0906556065 (BRTX )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
4
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
3
/ 7
Profile
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. Read full profile
Fundamentals
- Net revenue
€516.21K - Gross margin
94.5% - EBIT
-€11.17M - EBIT margin
-2,162.9% - Net income
-€9.15M - Net margin
-1,771.9%
Statement period: - (published )
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
No insider transactions in the last 90 days. View older insider transactions
Earnings Calls
Earnings Calls
Latest earnings call: May 14, 2024 (Q1 2024)